MIMS Group, a healthcare technology company with over 60 years of trusted medical data, is embarking on a significant transformation aimed at global expansion and product innovation. The company is leveraging its extensive medicines information, clinical decision support, and medical communications expertise to build new technology platforms and services. This move matters because it signals a strategic shift from traditional information provision to scalable, AI-enabled solutions that could improve clinical workflows and patient outcomes across 17 markets.
Under the leadership of Group CEO Sohil Goswami, appointed in January 2026, MIMS has restructured its businesses to accelerate growth. The company recently launched MIMS Pulse, a next-generation Clinical Decision Support (CDS) platform that integrates MIMS' medicines data with modern technology for flexible deployment and integration, supporting safer and more efficient clinical workflows. Alongside this, MIMS is scaling eMIMS Plus, a digital platform that brings trusted medicines information into a modern user experience. Originally launched in Australia, eMIMS Plus is now available in India and Malaysia, with plans to expand across Southeast Asia and introduce new clinical modules, including through Drugs4Dent.
The implications of these developments are far-reaching. For healthcare professionals, MIMS' enhanced CDS offerings mean access to reliable, up-to-date drug information at the point of care, potentially reducing medication errors and improving decision-making. For the life sciences industry, MIMS' expanding Medical Communications business—now with commercial capabilities in the US and UK—opens new avenues for engaging healthcare professionals through digital events, AI-enabled content, and intelligence-led services. This positions MIMS as a competitor in the global healthcare technology arena, moving beyond its traditional Asia-Pacific focus.
Goswami emphasized the strategic importance: "For decades, healthcare professionals have trusted MIMS' medicines information and expertise. Today, we are transforming that foundation into the next generation of digital products, platforms and services. Our opportunity is to turn trusted medical data, deep healthcare relationships and market knowledge into the next generation of products to build a MIMS that can compete and grow globally."
The company's evolution reflects broader trends in healthcare technology, where data-driven insights and AI are increasingly central to clinical decision support and medical marketing. By scaling its platforms and entering new markets, MIMS aims to capture a larger share of the global healthcare technology market. The success of this transformation will depend on its ability to integrate its legacy data with cutting-edge technology while maintaining the trust of healthcare professionals.
MIMS is present in 17 markets, including Singapore (headquarters), Australia, China, Germany, Hong Kong SAR, Indonesia, India, Ireland, Japan, Korea, Malaysia, New Zealand, Philippines, Taiwan, Thailand, UAE, and Vietnam. The issuer is solely responsible for the content of this announcement. For more information, visit https://corporate.mims.com/.
